Adynxx Inc. (ADYX)

Overview

Adynxx, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative solutions for pain and inflammatory diseases through its cutting-edge transcription factor decoy technologies. Founded in 2007, the company operates out of its headquarters in San Francisco, California. With a strong focus on addressing the unmet medical needs in postoperative pain and chronic pain conditions, Adynxx aims to revolutionize the treatment landscape through its proprietary AYX platform.

Products and Services

• Brivoligide

Brivoligide is Adynxx's flagship product currently in Phase II clinical development. It represents a novel approach in the reduction of postoperative pain by targeting transcription factor decoys. Its innovative mechanism has the potential to drastically improve pain management practices following surgical procedures, offering hope to millions of patients seeking effective pain relief without the side effects associated with traditional analgesics.

• AYX2

AYX2 is Adynxx's pre-clinical candidate specifically designed for the treatment of focal chronic pain. As a part of the company's AYX platform, AYX2 embodies the potential to target and mitigate chronic pain at its molecular roots. Still in the pre-clinical stage, AYX2 shows promise in addressing various forms of chronic pain, offering a glimpse into the future of personalized, targeted pain relief therapies.